Buy Beginner SARMs Stack UK | Ostarine + LGD-4033

What Is the Beginner Muscle Stack?

The Beginner Muscle Stack combines two of the most clinically studied SARMs available: Ostarine MK-2866 (Enobosarm) and LGD-4033 Ligandrol. This is a two-compound starter stack designed for researchers new to selective androgen receptor modulators who want an evidence-backed starting point with moderate potency.

If you’re looking to buy a beginner SARMs stack in the UK, sarms.co.uk supplies both compounds at 99%+ HPLC-verified purity with full Certificates of Analysis, GMP-certified UK manufacture, and free next-day delivery. Whether you’re searching for a SARMs starter stack UK, beginner SARM cycle, or the best SARMs for first cycle, this combination pairs the two compounds with the strongest clinical evidence base in the SARM field.

The logic behind this pairing is deliberate: both Ostarine and LGD-4033 have completed human clinical trials (unusual in the SARM space), both have moderate potency profiles that allow researchers to establish baseline response, and both have enough published data to inform dosing decisions. This is the most conservative multi-compound SARM protocol in our range.

What’s in the Beginner Muscle Stack?

Compound	Dose	Capsules	Classification	Human Trials
Ostarine MK-2866	10 mg per capsule	90	Non-steroidal SARM	Phase II and III (GTx/Enobosarm)
LGD-4033 Ligandrol	10 mg per capsule	90	Non-steroidal SARM	Phase I (Basaria et al., 2013) + Phase II (Viking Therapeutics VK5211)

90 capsules of each compound. Two bottles per stack.

Why Ostarine and LGD-4033 Together?

The rationale for combining these two specific SARMs is straightforward: complementary strengths with the strongest evidence base available.

Ostarine MK-2866: The Foundation

Ostarine is the most clinically studied SARM in existence. Developed by GTx Inc. as Enobosarm, it has completed Phase II and Phase III human clinical trials for cancer-related muscle wasting (cachexia). Key characteristics:

Lean mass preservation in caloric deficit: Demonstrated in human trials, making it particularly relevant for cutting and recomposition research protocols
Moderate anabolic potency: Effective without being aggressive, allowing researchers to establish baseline SARM response
Dose-dependent and generally well-tolerated: Human trial data at multiple dose levels provides clear pharmacological reference points
Longest clinical pipeline of any SARM: More published human safety data than any other compound in this class

Full compound details: Ostarine MK-2866 product page

LGD-4033 Ligandrol: Added Potency

LGD-4033 adds a step up in anabolic potency while maintaining a favourable selectivity profile. Developed initially by Ligand Pharmaceuticals, with clinical development continuing through Viking Therapeutics as VK5211. Key characteristics:

Statistically significant lean mass gains at 1 mg/day: The Phase I trial by Basaria et al. (2013) demonstrated measurable lean mass increases over just 21 days at the lowest dose tested
Higher binding affinity than Ostarine: Provides the stronger growth stimulus in the pairing
Phase II development ongoing: Viking Therapeutics continues clinical investigation for hip fracture recovery, adding to the evidence base
Still moderate compared to RAD-140 or YK-11: A meaningful step up from Ostarine without jumping to the most potent options

Full compound details: LGD-4033 Ligandrol product page

How the Beginner Stack Works: Mechanism of Action

Both compounds are selective androgen receptor modulators that bind to androgen receptors in skeletal muscle and bone tissue with preferential tissue selectivity over reproductive organs. The “selective” part is what distinguishes SARMs from traditional androgens: they activate androgen receptors in target tissues while producing substantially less stimulation in the prostate, seminal vesicles, and other androgen-sensitive tissues.

Complementary Binding Profiles

While both Ostarine and LGD-4033 target the same receptor, they have different binding affinities and pharmacokinetic profiles:

Ostarine has moderate binding affinity and a ~24-hour half-life, providing steady baseline AR activation
LGD-4033 has stronger binding affinity (approximately 10x that of Ostarine in preclinical assays) and a ~24-36 hour half-life, providing more potent anabolic signalling
The combination means consistent AR occupancy across a range of binding strengths, potentially engaging a broader spectrum of androgen-responsive gene expression than either compound alone

No Aromatisation

Neither compound undergoes aromatisation (conversion to oestrogen). There is no risk of oestrogenic side effects such as gynecomastia or water retention from this stack.

No DHT Conversion

Neither Ostarine nor LGD-4033 is converted to dihydrotestosterone. The androgenic effects are limited to direct AR binding with the tissue selectivity inherent to the SARM structure.

Who Is the Beginner Muscle Stack For?

Researchers new to SARMs who want the most evidence-backed starting point available
Those prioritising clinical evidence: both compounds have human trial data, which is rare in this space
Lean muscle preservation research protocols where moderate, controlled anabolic stimulus is preferred
Researchers establishing baseline response before progressing to more potent compounds or larger stacks
Cutting and recomposition protocols: Ostarine’s demonstrated lean mass preservation in caloric deficit makes this pairing well-suited for deficit research

Who Should Consider Other Stacks?

Experienced researchers who already know their response to individual SARMs: consider the Intermediate Stack (adds RAD-140 + MK-677) or the Advanced Stack (four compounds)
Maximum potency protocols: the Bulk Mass Stack includes YK-11 and RAD-140 in a single capsule for the most aggressive approach
Researchers wanting GH pathway support: the Intermediate and Advanced stacks include MK-677, which targets growth hormone secretion independently of androgen receptors

Beginner Stack vs Other Stacks: Which Is Right?

Feature	Beginner Stack	Intermediate	Advanced	Bulk Mass
Compounds	2 (MK-2866 + LGD-4033)	3 (LGD + RAD-140 + MK-677)	4 (LGD + MK-2866 + RAD-140 + MK-677)	4-in-1 capsule (MK-677 + LGD + RAD-140 + YK-11)
AR agonists	2 (moderate)	2 (moderate + potent)	3 (moderate x2 + potent)	3 (potent + potent + steroidal)
GH pathway	No	Yes (MK-677)	Yes (MK-677)	Yes (MK-677)
Human trial data	Both compounds	All three	All four	3 of 4 (YK-11 has in vitro only)
HPTA suppression risk	Moderate	Higher	Highest (3 AR agonists)	Highest (3 AR agonists)
Dose flexibility	Full (separate bottles)	Full	Full	None (fixed ratio single capsule)
Best for	First cycle, evidence priority	Second cycle, multi-pathway	Experienced, comprehensive	Experienced, maximum potency

Dosage and Administration (Research Use Only)

Ostarine MK-2866: 10 mg per capsule, 90 capsules per bottle
LGD-4033 Ligandrol: 10 mg per capsule, 90 capsules per bottle
Typical research cycle: 8-12 weeks
Administration: Both are oral capsules, typically taken once daily. Both compounds can be taken at the same time

No human clinical trials have established optimal dosing for this specific combination. The individual compound dosages are based on single-agent clinical trial data. Researchers should consult the individual product pages for detailed dosing information based on published clinical data:

Side Effects and Safety Considerations

HPTA Suppression

Both Ostarine and LGD-4033 cause dose-dependent HPTA suppression. When stacked, the combined androgen receptor load increases the likelihood and degree of testosterone, LH, and FSH suppression compared to either compound alone. This is the primary safety consideration with this stack.

Lipid Changes

Both compounds may cause mild HDL suppression. This is a class effect observed with all AR agonists. The combination may produce a more pronounced effect than either compound individually.

Liver Considerations

Clinical trial data for both compounds showed generally mild liver enzyme profiles at therapeutic doses. However, combining two oral compounds increases hepatic processing demands. Baseline and periodic liver panel monitoring is standard practice in research protocols.

What This Stack Does NOT Cause

No oestrogenic effects (neither compound aromatises)
No DHT-related effects (neither converts to DHT)
No water retention beyond normal intramuscular hydration
No androgenic side effects typical of traditional steroids (hair loss, prostate enlargement) at the same incidence

Does the Beginner Stack Require PCT?

Yes. Both compounds cause dose-dependent HPTA suppression, and the combined use of two AR agonists increases suppression potential. Many researchers include post-cycle therapy protocols as standard practice when using this stack, particularly at higher doses or for longer cycles (10+ weeks).

The degree of suppression varies individually. Some researchers report minimal suppression at lower doses of this combination, while others experience more significant hormonal impact. Blood work before, during, and after the cycle is the only reliable way to assess individual response.

For PCT compound options, the individual product pages for Ostarine and LGD-4033 discuss PCT considerations in detail.

Published Research Supporting This Combination

Ostarine (MK-2866/Enobosarm)

Phase III POWER trials: Dalton et al. (2011) demonstrated lean body mass increases and physical function improvements in cancer patients with muscle wasting. PMID: 21527404
Phase II: Dobs et al. (2013) reported dose-dependent lean mass gains in cancer cachexia patients. PMID: 23463733

LGD-4033 (Ligandrol/VK5211)

Phase I: Basaria et al. (2013) demonstrated statistically significant lean mass gains at 1 mg/day over 21 days in healthy volunteers. PMID: 22459616
Phase II: Viking Therapeutics’ VK5211 trial for hip fracture recovery showed improvements in lean body mass and functional measures

No published research exists on this specific two-compound combination. The rationale for stacking is based on complementary mechanisms and the individual evidence base for each compound.

Why Buy the Beginner Stack from sarms.co.uk?

99%+ HPLC-Verified Purity

Both compounds are independently tested via High-Performance Liquid Chromatography by accredited third-party laboratories. Full Certificates of Analysis available for every batch. Download the PDFs directly from this page.

GMP-Certified UK Manufacture

Both products are compounded in GMP-certified facilities in the United Kingdom. Not imported from unregulated overseas laboratories. Raw materials tested before compounding, finished products tested after.

Stack Savings

Purchasing as a stack saves compared to buying each compound individually. Same quality, better value.

Separate Bottles for Dose Flexibility

Unlike single-capsule combination products, this stack provides each compound in its own bottle. This allows researchers to adjust individual compound doses independently, run one compound at a higher or lower dose than the other, or discontinue one compound mid-cycle if needed.

Free Next-Day UK Delivery

All orders ship free with next-day UK delivery. No minimum order, no hidden shipping fees.

Frequently Asked Questions About the Beginner Muscle Stack

Is this stack suitable for a first SARM cycle?

Yes. Both Ostarine and LGD-4033 have human clinical trial data, moderate potency profiles, and are among the best-characterised SARMs available. This is the most evidence-backed starting point for researchers new to selective androgen receptor modulators.

Do I need PCT with this stack?

Both compounds cause dose-dependent HPTA suppression. Combining two AR agonists increases suppression potential compared to either alone. Most researchers include PCT protocols as standard practice, particularly at higher doses or for cycles longer than 8 weeks.

Can I take both compounds at the same time?

Yes. Both are oral capsules typically administered once daily. They can be taken together at the same time of day.

What is the difference between this and the Intermediate Stack?

The Beginner Stack uses two moderate-potency SARMs with the strongest clinical evidence. The Intermediate Stack adds a third compound (RAD-140, a more potent AR agonist) plus MK-677 (a growth hormone secretagogue), introducing a second growth pathway and greater overall potency.

How long should I run the Beginner Stack?

Most research protocols reference 8-12 weeks for this combination. Shorter cycles (6-8 weeks) may be appropriate for researchers prioritising minimal suppression. Longer cycles increase cumulative HPTA impact.

Will this stack cause water retention?

Neither Ostarine nor LGD-4033 aromatises to oestrogen, so there is no oestrogen-mediated water retention. Some researchers report mild intramuscular hydration effects, but this is distinct from the bloating associated with oestrogenic compounds.

Can I add MK-677 to this stack?

Yes. Adding MK-677 Ibutamoren to this stack is essentially building a custom version of the Advanced Stack (minus RAD-140). MK-677 targets the GH/IGF-1 axis independently of androgen receptors and does not add HPTA suppression.

Is the Beginner Stack good for cutting?

Yes. Ostarine’s demonstrated ability to preserve lean mass in caloric deficit (shown in human trials) makes this combination particularly well-suited for cutting and recomposition research. LGD-4033 adds anabolic stimulus to counteract muscle catabolism during energy restriction.

What results can I expect from the Beginner Stack?

No clinical trial has studied this specific combination, so expected outcomes are extrapolated from individual compound data. The LGD-4033 Phase I trial showed lean mass gains at 1 mg/day over 21 days. Ostarine trials showed lean mass preservation in catabolic conditions. Individual response varies significantly based on dose, diet, training, and genetics.

Is this stack legal in the UK?

Both Ostarine and LGD-4033 are legal to purchase in the UK for research purposes. Neither is approved for human consumption by the MHRA. Both are on WADA’s prohibited list and cannot be used in competitive sport.

How does this compare to buying the compounds separately?

The stack contains the same products at the same quality and purity. The only difference is pricing: purchasing as a stack saves compared to individual purchases. The compounds are supplied in separate bottles, so there is no difference in product quality or dose flexibility.

Should I start with one compound before stacking?

Some researchers prefer to run single-compound cycles first to isolate their response to each SARM individually. This approach makes it easier to identify which compound is responsible for any effects (positive or negative). Others start directly with the stack. Neither approach has clinical evidence supporting its superiority.

References

Dalton JT, et al. (2011). “The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women.” J Cachexia Sarcopenia Muscle, 2(3), 153-161. PMID: 21527404
Dobs AS, et al. (2013). “Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.” Lancet Oncol, 14(4), 335-345. PMID: 23463733
Basaria S, et al. (2013). “The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.” J Gerontol A Biol Sci Med Sci, 68(1), 87-95. PMID: 22459616

Disclaimers

This stack is sold strictly for laboratory and research purposes only
These products are not intended for human consumption
Not medicines, supplements, or food products
Not suitable for individuals under 18 years of age
Pregnant or breastfeeding women must not handle these compounds
Researchers should consult qualified professionals and adhere to all applicable regulations
sarms.co.uk does not provide medical advice and makes no claims regarding therapeutic outcomes
The content on this page does not constitute medical advice

Content last reviewed: 17 February 2026

Reviews

There are no reviews yet

Be the first to review “Beginner Stack”

You must be logged in to post a review.

Featured

Our Products

Beginner Stack